Revolutionizing at‐home testing of blood‐based p ‐tau217 for early detection of Alzheimer's disease: A validation study of the Tasso Lancet Device

Abstract

Background: P‐tau217 is emerging as the most accurate blood‐based biomarker (BBBM) for the diagnosis of Alzheimer's disease (AD) pathology, with elevated levels correlating with β‐amyloid and tau pathology, as confirmed by PET scans and cerebrospinal fluid analysis.

The paper